Protara Therapeutics, Inc. (TARA) is a New York-based clinical-stage biopharmaceutical company focused on pioneering innovative therapies for cancer and rare diseases. Leveraging advanced drug delivery technologies, Protara aims to enhance therapeutic outcomes for patients facing significant unmet medical needs. The company is advancing a robust pipeline of treatments and engaging in strategic collaborations, positioning itself to make a valuable impact on the healthcare sector while creating substantial shareholder value. Show more
Location: 345 PARK AVENUE SOUTH, NEW YORK, NY, UNITED STATES, 10010, New York, NY, 10010, USA | Website: https://www.protaratx.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE
Market Cap
379.4M
52 Wk Range
$2.77 - $7.82
Previous Close
$7.08
Open
$7.06
Volume
528,464
Day Range
$6.99 - $7.29
Enterprise Value
246.1M
Cash
12.55M
Avg Qtr Burn
-12.45M
Insider Ownership
2.26%
Institutional Own.
53.88%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
IV Choline chloride Details Intestinal failure associated liver disease, Long-term parenteral support | Phase 2/3 Data readout | |
TARA-002 Details Non-muscle invasive bladder cancer | Phase 2 Data readout | |
TARA-002 Details Lymphatic malformations (LMs) | Phase 2 Update |